title: [New developments in the treatment of pancreatic cancer].
abstract: - The incidence of pancreatic cancer is increasing due to the ageing population among other things, while 5-year survival has improved in the past two decades from 3 to 7%.- In case of biliary obstruction due to pancreatic cancer, biliary drainage before surgery or ablative therapy using a covered metal stent instead of plastic reduces the rate of complications.- In patients with metastasized pancreatic cancer a combination of folinic acid, fluorouracil, irinotecan and oxaliplatin (FOLFIRINOX) results in improved survival. Approximately 20% of patients with locally, unresectable pancreatic cancer can undergo surgical resection following treatment with FOLFIRINOX.- The effectiveness of radiofrequency ablation, irreversible electroporation and stereotactic radiotherapy for locally, unresectable pancreatic cancer is currently investigated in multicenter trials.- The effectiveness of neo-adjuvant chemoradiation and minimal invasive surgery in patients with resectable pancreatic cancer is currently investigated in randomized multicenter trials.
authors.affiliation: Dutch Pancreatic Cancer Group.
authors.forename: H A
authors.initials: HA
authors.lastname: Marsman
authors.forename: M G
authors.initials: MG
authors.lastname: Besselink
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D002779:Cholestasis / Q000209:etiology / Q000628:therapy; D006801:Humans; D020360:Neoadjuvant Therapy; D010180:Pancreatectomy / Q000379:methods; D010190:Pancreatic Neoplasms / Q000150:complications / Q000628:therapy*; D018714:Radiotherapy, Adjuvant; D015607:Stents
chemical_list: D000970:Antineoplastic Agents